Faruqi and Faruqui, LLP Logo
Share this page

Puma Biotechnology Inc. (PBYI)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm

 Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Puma Biotechnology, Inc. (“Puma Biotechnology” or the “Company”) (NASDAQ:PBYI)

The investigation focuses on whether the Company and its executives violated federal securities laws.  Specifically, on May 5, 2017, the Company disclosed the resignation of the Company's Senior Vice President, citing “health reasons.”  Dr. Charnas’s resignation will be effective as of May 15, 2017, nine days before the U.S. Food and Drug Administration’s scheduled review of Puma’s breast cancer drug neratinib on May 24, 2017.

After the announcement, Puma Biotechnology’s share price fell from $36.55 per share on May 4, 2017 to $29.85 during intraday trading on May 5, 2017—a $6.70 or a 18.08% drop.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Puma Biotechnology Inc. (PBYI)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 05/05/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.